Dr. Saby George Dr. Saby George

Saby George

MD, FACP
Medical Oncology

Specializing In:

Kidney Cancer Prostate Cancer Bladder Cancer

Special Interests:

Kidney cancer: My interests include clinical trials, novel drug development, mechanism of resistance formation to tyrosine kinase inhibitors, improving the response evaluation criteria and development of biomarkers. Prostate cancer: Castrate refractory prostate cancer, high Gleason score disease, improving androgen deprivation therapy and biomarker development.

About Saby George

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology and Medicine
  • Director of Network Clinical Trials
  • Department of Medicine
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
  • Associate Professor

Background

Education and Training:

  • Kottayam Medical College, Kerala, India

Residency:

  • Wright State University, Dayton, OH

Fellowship:

  • Experimental therapeutics-Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
  • Medical Oncology-University of Texas Health Sciences Center at San Antonio, San Antonio, TX

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Clinical Trials


Featured on Cancer Talk


Publications

Full Publications list on PubMed
  1. Motzer RJ, Tannir NM, McDermott DF, Aren Fontera O, Melichar, B Choueiri TK, Barthelemy,P Porta C, George, S. et al., Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. https://pubmed.ncbi.nlm.nih.gov/29562145/
  2. Motzer R, Escudier B, McDermott D, George S, Hammers H, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack E, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono PJ, Wagstaff J, Gauler T, Ueda T, Tomita Y, Schultz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon J, Xu L, Waxman I, Sharma P, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.  New England Journal of Medicine.  2015 Sept; DOl:  10.1056/NEJMoa1510665. https://pubmed.ncbi.nlm.nih.gov/26406148/
  3. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, Alva A, Haas N, Harrison MR, Plimack ER, Sosman J, Agarwal N, Bhayani S, Choueiri TK, Costello BA, Derweesh IH, Gallagher TH, Hancock SL, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Lewis B, Manley B, McCreery B, McDonald A, Mortazavi A, Pierorazio PM, Ponsky L, Redman BG, Somer B, Wile G, Dwyer MA; CGC, Hammond LJ, Zuccarino-Catania G.  NCCN Guidelines Insights: Kidney Cancer, Version2.2020 J Natl Compr Canc Netw. 2019 Nov 1;17(11):1278-1285. doi: 10.6004/jnccn.2019.0054.PMID:31693980. https://pubmed.ncbi.nlm.nih.gov/31693980/
  4. Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, EscudierB, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison M..et al., Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019 Aug 16. pii: S1470-2045(19)30413-9. doi: 10.1016/S1470-2045(19)30413-9. [Epub ahead of print] Erratum in: Lancet Oncol. 2019 Aug 21:PMID:31427204. https://pubmed.ncbi.nlm.nih.gov/31427204/
  5. Fong L, Hotson A, Powderly JD, Sznol M, Heist RS, Choueiri TK, George S, Hughes BGM, Hellmann MD, Shepard DR, Rini BI, Kummar S, Weise AM, Riese MJ, Markman B, Emens LA, Mahadevan D, Luke JJ, Laport G, Brody JD, Hernandez-Aya L, Bonomi P, Goldman JW, Berim L, Renouf DJ, Goodwin RA, Munneke B, Ho PY, Hsieh J, McCaffery I, Kwei L, Willingham SB, Miller RA.  Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment Refectory Renal Cell Carcinoma Cancer Discov. 2020 Jan;10(1):40-53. doi: 10.1158/2159-8290.CD-19-0980. Epub 2019 Nov 15. PMID: 31732494. https://pubmed.ncbi.nlm.nih.gov/31732494/
  6. Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan, A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR,Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC. Cabozantinib in advanced  non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28. PMID:308277. https://pubmed.ncbi.nlm.nih.gov/30827746/
  7. Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, Gupta S, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal SK. Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC). J Clin Oncol. 2020 Apr 9:JCO1903091. doi: 10.1200/JCO.19.03091. [Epub ahead of print]. https://pubmed.ncbi.nlm.nih.gov/32271672/
  8. Tannir NM, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, Flaifel A, Pignon JC, Ficial M, Frontera OA, George S, Powles T, Donskov F, Harrison MR, Barthélémy P, Tykodi SS, Kocsis J, Ravaud A, Rodriguez-Cid JR, Pal SK, Murad AM, Ishii Y, Saggi SS, McHenry MB, Rini BI. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020 Sep 1. doi: 10.1158/1078-0432.CCR-20-2063. Online ahead of print. https://pubmed.ncbi.nlm.nih.gov/32873572/
  9. Escudier B, Motzer RJ, Sharma P, Wagstaff J, Plimack ER, Hammers HJ, Donskov F, Gurney H, Sosman JA, Zalewski PG, Harmenberg U, McDermott DF, Choueiri TK, Richardet M, Tomita Y, Ravaud A, Doan J, Zhao H, Hardy H, George S. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. Eur Urol. 2017 Apr 12. pii: S0302-2838(17)30265-8. doi: 10.1016/j.eururo.2017.03.037. [Epub ahead of print] PMID: 28410865. https://pubmed.ncbi.nlm.nih.gov/28410865/
  10. George S, Motzer RJ,   Hammers HJ,  Redman BG,  Kuzel TM,  Tykodi SS,  Plimack ER,  Jiang J,  Waxman IM,  Rini BI.  Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond ProgressionJAMA Oncol. Published online May 12, 2016. doi:10.1001/jamaoncol.2016.0775. https://pubmed.ncbi.nlm.nih.gov/27243803/

Request an Appointment

Make an appointment by calling 1-800-ROSWELL (1-800-767-9355)

Make an Appointment

See what others are saying about Saby George, MD, FACP, and leave your own review.

Reputation Reviews

Leave a Review